Page 1

PYC Therapeutics September 22 , 2021 Annual Report for the year ended 30th June 2021 PYC Therapeutics Limited ( " PYC " or " the Company " ) submits its Annual Report for the year ended 30th June 2021 . This announcement has been approved for release by the Board of PYC Therapeutics Limited . For further information , please contact : Kevin Hart Company Secretary For personal use only +61 8 9316 9100 info@pyctx.com About PYC Therapeutics PYC Therapeutics ( ASX : PYC ) is a development - stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines . PYC believes its PPMO ( Peptide conjugated Phosphorodiamidate Morpholino Oligomer ) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today . The Company is leveraging its leading - edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases . PYC's discovery and laboratory operations are located in Australia , and the Company's preclinical , clinical , regulatory and corporate operations are based in San Diego , California . For more information , visit pyctx.com , or follow us on LinkedIn and Twitter . CONTACTS : INVESTORS Deborah Elson / Matthew DeYoung MEDIA Argot Partners 0994 deborah@argotpartners.com pyctx.com ACN 098 3919 Leo Vartorella Argot Partners leo@argotpartners.com 1 matthew@argotpartners.com